Cargando…

Different expression patterns of VISTA concurrent with PD-1, Tim-3, and TIGIT on T cell subsets in peripheral blood and bone marrow from patients with multiple myeloma

V-type immunoglobulin domain-containing suppressor of T cell activation (VISTA) is considered as an immunosuppressive factor and potential therapeutic target for anticancer therapy. However, little is known about VISTA expression and its role in immunosuppression in multiple myeloma (MM). In this st...

Descripción completa

Detalles Bibliográficos
Autores principales:	Huang, Shuxin, Zhao, Yujie, Liao, Pengjun, Wang, Jinghua, Li, Zhiyan, Tan, Jiaxiong, Zha, Xianfeng, Chen, Shaohua, Li, Yangqiu, Zhong, Liye
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9684650/ https://www.ncbi.nlm.nih.gov/pubmed/36439426 http://dx.doi.org/10.3389/fonc.2022.1014904

Ejemplares similares

Targeting LAG-3, TIM-3, and TIGIT for cancer immunotherapy
por: Cai, Letong, et al.
Publicado: (2023)

Correction: Targeting LAG-3, TIM-3, and TIGIT for cancer immunotherapy
por: Cai, Letong, et al.
Publicado: (2023)

Increased TOX expression associates with exhausted T cells in patients with multiple myeloma
por: Zhao, Yujie, et al.
Publicado: (2022)

Increased PD-1+Tim-3+ exhausted T cells in bone marrow may influence the clinical outcome of patients with AML
por: Tan, Jiaxiong, et al.
Publicado: (2020)

PD-1 and TIGIT Are Highly Co-Expressed on CD8(+) T Cells in AML Patient Bone Marrow
por: Xu, Ling, et al.
Publicado: (2021)

Higher TOX Genes Expression Is Associated With Poor Overall Survival for Patients With Acute Myeloid Leukemia
por: Liang, Chaofeng, et al.
Publicado: (2021)

Bone Marrow-Resident Vδ1 T Cells Co-express TIGIT With PD-1, TIM-3 or CD39 in AML and Myeloma
por: Brauneck, Franziska, et al.
Publicado: (2021)

TIM-3 in Leukemia; Immune Response and Beyond
por: Rezaei, Mahnaz, et al.
Publicado: (2021)

Targeting TIM-3 for hematological malignancy: latest updates from the 2022 ASH annual meeting
por: Tan, Jiaxiong, et al.
Publicado: (2023)

High Co-Expression of PDCD1/TIGIT/CD47/KIR3DL2 in Bone Marrow Is Associated with Poor Prognosis for Patients with Myelodysplastic Syndrome
por: Zhong, Mengjun, et al.
Publicado: (2023)

Increased Expression of TIGIT/CD57 in Peripheral Blood/Bone Marrow NK Cells in Patients with Chronic Myeloid Leukemia
por: Yao, Danlin, et al.
Publicado: (2020)

Age related human T cell subset evolution and senescence
por: Li, Mingde, et al.
Publicado: (2019)

Re-balance of memory T cell subsets in peripheral blood from patients with CML after TKI treatment
por: Yao, Danlin, et al.
Publicado: (2017)

Profiling the inhibitory receptors LAG-3, TIM-3, and TIGIT in renal cell carcinoma reveals malignancy
por: Takamatsu, Kimiharu, et al.
Publicado: (2021)

Single-cell profiling of T cells uncovers a tissue-resident memory-like T-cell subset associated with bidirectional prognosis for B-cell acute lymphoblastic leukemia
por: Lai, Wenpu, et al.
Publicado: (2022)

Tissue-Specific Expression of TIGIT, PD-1, TIM-3, and CD39 by γδ T Cells in Ovarian Cancer
por: Weimer, Pauline, et al.
Publicado: (2022)

Comprehensive analysis of the immune pattern of T cell subsets in chronic myeloid leukemia before and after TKI treatment
por: Yao, Danlin, et al.
Publicado: (2023)

Tim-3 signaling blockade with α-lactose induces compensatory TIGIT expression in Plasmodium berghei ANKA-infected mice
por: Zhang, Yiwei, et al.
Publicado: (2019)

Memory T cells skew toward terminal differentiation in the CD8+ T cell population in patients with acute myeloid leukemia
por: Xu, Ling, et al.
Publicado: (2018)

TOX as a potential target for immunotherapy in lymphocytic malignancies
por: Liang, Chaofeng, et al.
Publicado: (2021)

Incidence and effect of secondary cardiac amyloidosis on outcomes of patients with t(11;14) multiple myeloma
por: Wang, Jinghua, et al.
Publicado: (2022)

Identification of TCR Vβ11-2-Dβ1-Jβ1-1 T cell clone specific for WT1 peptides using high-throughput TCRβ gene sequencing
por: Zhang, Yikai, et al.
Publicado: (2019)

Expression of Immune Checkpoint Regulators IDO, VISTA, LAG3, and TIM3 in Resected Pancreatic Ductal Adenocarcinoma
por: Popp, Felix C., et al.
Publicado: (2021)

Addition of anti-TIM3 or anti-TIGIT Antibodies to anti-PD1 Blockade Augments Human T cell Adoptive Cell Transfer
por: Martinez, Marina, et al.
Publicado: (2021)

Increased coexpression of PD-L1 and TIM3/TIGIT is associated with poor overall survival of patients with esophageal squamous cell carcinoma
por: Wang, Peipei, et al.
Publicado: (2021)

Single‐Cell RNA‐Seq of T Cells in B‐ALL Patients Reveals an Exhausted Subset with Remarkable Heterogeneity
por: Wang, Xiaofang, et al.
Publicado: (2021)

TIGIT(+) TIM-3(+) NK cells are correlated with NK cell exhaustion and disease progression in patients with hepatitis B virus‑related hepatocellular carcinoma
por: Yu, Lihua, et al.
Publicado: (2021)

Generation of diffuse large B cell lymphoma-associated antigen-specific Vα6/Vβ13+T cells by TCR gene transfer
por: Yin, Qingsong, et al.
Publicado: (2011)

Evolution of T-cell clonality in a patient with Ph-negative acute lymphocytic leukemia occurring after interferon and imatinib therapy for Ph-positive chronic myeloid leukemia
por: Wang, Liang, et al.
Publicado: (2010)

TIGIT in cancer immunotherapy
por: Chauvin, Joe-Marc, et al.
Publicado: (2020)

Quantitative and functional characteristics of circulating and bone marrow PD-1- and TIM-3-positive T cells in treated multiple myeloma patients
por: Batorov, Egor V., et al.
Publicado: (2020)

Immune checkpoint alterations and their blockade in COVID-19 patients
por: Tan, Jiaxiong, et al.
Publicado: (2022)

Increased co-expression of TIM-3 with TIGIT or 2B4 on CD8+ T cells is associated with poor prognosis in locally advanced nasopharyngeal carcinoma
por: Xie, Xiaolin, et al.
Publicado: (2023)

TIGIT expressing CD4+T cells represent a tumor-supportive T cell subset in chronic lymphocytic leukemia
por: Catakovic, Kemal, et al.
Publicado: (2017)

CD155/TIGIT signalling plays a vital role in the regulation of bone marrow mesenchymal stem cell–induced natural killer–cell exhaustion in multiple myeloma
por: Liu, Zhao‐Yun, et al.
Publicado: (2022)

TIGIT is a key inhibitory checkpoint receptor in lymphoma
por: Godfrey, James, et al.
Publicado: (2023)

Study on the Effect of EZH2 Inhibitor Combined with TIGIT Monoclonal Antibody against Multiple Myeloma Cells
por: Liu, Zhaoyun, et al.
Publicado: (2023)

Increased frequency of TIGIT+ CD4 T Cell subset in autoantibody-positive first-degree relatives of patients with rheumatoid arthritis
por: Anaparti, Vidyanand, et al.
Publicado: (2022)

The TIGIT(+) T regulatory cells subset associates with nosocomial infection and fatal outcome in COVID-19 patients under mechanical ventilation
por: de Lima, Mikhael Haruo Fernandes, et al.
Publicado: (2023)

Bone marrow‐derived mesenchymal stem cells inhibit NK cell function via Tim‐3/galectin‐9 in multiple myeloma patients
por: Liu, Zhao‐Yun, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_klhtqa4kc8rc20f8un74emuaoa